OTC · NEXI
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Sep 17, 2026, 5:30 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NEXI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NEXI.
NEXI research
Company profile and research snapshot.
NEXIMMUNE INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 16, 2022 | Cantor Fitzgerald | Neutral | — |
| Nov 15, 2022 | Raymond James | Market Perform | — |
| Aug 16, 2022 | Raymond James | Outperform | — |
| Aug 16, 2022 | Barclays | Overweight | — |
| Jun 1, 2022 | BTIG | Buy | — |
No generated briefing is available yet.
defenseworld.net · Dec 10, 2025
Earnings and Valuation This table compares NexImmune and IMV"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NexImmune N/A N/A -$32.34 million ($18.29) N/A IMV $330,000.00 0.00 -$37.99 million ($4.59) N/A NexImmune has higher earnings, but lower revenue than IMV. Risk and Volatility NexImmune has
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NEXI.
No results
No recent SID articles mention NEXI.
